A phase I trial of the FGFR inhibitor rogaratinib showed safety and efficacy in advanced cancers.
Splicing factor mutations increased protein arginine methyltransferase (PRMT) inhibitor sensitivity.
Combined entity may expand range of diagnostic tests beyond Cologuard, Oncotype DX.
Adaptive transfer of engineered T cells promoted tumor regression and objective responses in epithelial cancer.
A mutation in the little-studied gene RABL3 was found in a family with a history of PDAC.
Distinct tumor microbiomes are associated with long- and short-term survival in patients with PDAC.
Cancer cells using alternative lengthening of telomeres (ALT) require RAD51AP for telomere maintenance.
Preliminary results suggest that the PD-1 inhibitor plus chemo elicits a higher pCR rate than chemo alone.
The transcription factor BORIS promotes resistance-associated chromatin regulatory interactions.
Fructosamine-3-kinase (FN3K) activity promotes oncogenesis in models of liver and lung cancer.
Novel platform for making vaccines and immunomodulatory factors shows promise in early-stage testing.
T cell–based approach considered safe, generated responses in patients with advanced disease.
Loss of p53 caused increased neutrophil levels and systemic inflammation in mice with breast tumors.
Differentiated AML-derived cells are able to revert into leukemogenic states.
Tumor-expressed CD24 interacts with macrophage-expressed Siglec-10 to evade immune detection.
The immune response to checkpoint blockade is associated with recruitment of new T cells, not preexisting TILs.
Tailored agent stimulates immune response to unique combinations of neoantigens.
Methylation-based assay can determine whether patients have cancer and where the disease originated.
Molecule may increase number of targetable RAS mutations.
Antibody–drug conjugate may be effective for patients with treatment-resistant breast cancer.
Tregs promote M2-like TAM activity by limiting the secretion of IFNγ by CD8+ T cells.
The oncoprotein HER2 inhibits the cGAS–STING-mediated innate immune response to cytosolic DNA.
Ferroptotic cell death is mediated by cell contact and Hippo pathway members, including NF2 and YAP.
Estrogen receptor (ER) ligands’ antagonism is dictated by their effects on intranuclear ER mobility.
In a phase II trial, almost half of patients treated with SM-88 experienced partial responses or stable disease.
ICB response in mice could be predicted by pretreatment Stat1 expression and depended on NK cells.
Tisagenlecleucel has an acceptable safety profile and showed preliminary evidence of CNS efficacy.
Low-dose ionizing radiation (LDIR) induces proliferation of Trp53-mutant, but not wild-type, cells.
AML cells not expressing ligands of NKG2D had leukemic stem cell (LSC) activity linked to immune evasion.
Dasatinib suppresses CAR T-cell function without affecting viability; its impact is also reversible upon drug removal.
Drug developers and evolutionary biologists will develop treatment strategies that head off cancer evolution.
T cells engineered to express WT1 engraft, persist, and prolong relapse-free survival.
OnlineFirst articles are published online before they appear in a regular issue of the journal. Cancer Discovery publishes two types of OnlineFirst articles.
OnlineFirst Author Manuscripts are PDF versions of manuscripts that have been peer reviewed and accepted for publication, but not yet copyedited or typeset, allowing readers the most rapid access to accepted papers. They appear on the OnlineFirst page as submitted by the authors. The Author Manuscript remains on the OnlineFirst page until it is either replaced by the final proof version or when the final version of the paper is published in an online issue.
Please note that while we strive to post all accepted manuscripts within two days of their acceptance, there may be editorial considerations, such as a planned press release or the need to coordinate posting of related articles, which may preclude or delay Author Manuscript posting.
Author Manuscripts are normally replaced on the OnlineFirst page by the final proof version of the article, which incorporates author corrections but is not yet paginated.
When papers are published in an issue, they are removed from the OnlineFirst page and appear in the appropriate issue's table of contents. The date of first publication appears below each title, followed by the article's unique Digital Object Identifier (DOI).
While an article is OnlineFirst, it may be cited as shown in the following example:
Elizabeth A. Platz et al. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment (April 1, 2011) Cancer Discov, 10.1158/2159-8274.CD-10-0020.
Sign up to be notified each time OnlineFirst articles are posted in Cancer Discovery.
